Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deli… Read more
Arecor Therapeutics PLC (AREC) - Net Assets
Latest net assets as of June 2025: GBX2.86 Million GBX
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has net assets worth GBX2.86 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX5.25 Million) and total liabilities (GBX2.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX2.86 Million |
| % of Total Assets | 54.4% |
| Annual Growth Rate | 20.12% |
| 5-Year Change | 591.28% |
| 10-Year Change | N/A |
| Growth Volatility | 769.46 |
Arecor Therapeutics PLC - Net Assets Trend (2017–2024)
This chart illustrates how Arecor Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arecor Therapeutics PLC (2017–2024)
The table below shows the annual net assets of Arecor Therapeutics PLC from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX5.35 Million | -43.85% |
| 2023-12-31 | GBX9.53 Million | -45.42% |
| 2022-12-31 | GBX17.45 Million | -5.90% |
| 2021-12-31 | GBX18.55 Million | +2297.17% |
| 2020-12-31 | GBX773.79K | -75.88% |
| 2019-12-31 | GBX3.21 Million | -23.91% |
| 2019-05-31 | GBX4.22 Million | +528.92% |
| 2018-05-31 | GBX670.33K | -49.66% |
| 2017-05-31 | GBX1.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arecor Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4065026000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX378.00K | 7.07% |
| Other Comprehensive Income | GBX15.24 Million | 285.01% |
| Other Components | GBX34.68 Million | 648.42% |
| Total Equity | GBX5.35 Million | 100.00% |
Arecor Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Arecor Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Song Da Industry Trade JSC
VN:STP
|
$3.33K |
|
Viet Thai Electric Cable Corp
VN:VTH
|
$3.34K |
|
Kelani Valley Plantations PLC
CM:KVALN0000
|
$3.34K |
|
United Company RUSAL PLC Regist
STU:R6L
|
$3.34K |
|
10 Yr Variable Rate
KAR:P10VRR211034
|
$3.33K |
|
Rimac Seguros y Reaseguros
LIM:RIMSEGC1
|
$3.33K |
|
HAREL MALLAC LTD
SEM:HML
|
$3.33K |
|
Synergy Grid and Development Phils Inc
PSE:SGP
|
$3.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arecor Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,527,000 to 5,349,000, a change of -4,178,000 (-43.9%).
- Net loss of 10,236,000 reduced equity.
- New share issuances of 6,417,000 increased equity.
- Other comprehensive income increased equity by 278,000.
- Other factors decreased equity by 637,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-10.24 Million | -191.36% |
| Share Issuances | GBX6.42 Million | +119.97% |
| Other Comprehensive Income | GBX278.00K | +5.2% |
| Other Changes | GBX-637.00K | -11.91% |
| Total Change | GBX- | -43.85% |
Book Value vs Market Value Analysis
This analysis compares Arecor Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 434.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2870.22x to 434.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-05-31 | GBX0.02 | GBX69.50 | x |
| 2019-05-31 | GBX0.15 | GBX69.50 | x |
| 2019-12-31 | GBX0.12 | GBX69.50 | x |
| 2020-12-31 | GBX0.03 | GBX69.50 | x |
| 2021-12-31 | GBX0.81 | GBX69.50 | x |
| 2022-12-31 | GBX0.60 | GBX69.50 | x |
| 2023-12-31 | GBX0.31 | GBX69.50 | x |
| 2024-12-31 | GBX0.16 | GBX69.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arecor Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -191.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -202.57%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.63x
- Recent ROE (-191.36%) is below the historical average (-127.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -166.97% | -82.90% | 0.65x | 3.08x | GBX-1.19 Million |
| 2019 | -57.77% | -325.72% | 0.14x | 1.29x | GBX-2.86 Million |
| 2019 | -68.25% | -115.79% | 0.44x | 1.34x | GBX-2.51 Million |
| 2020 | -355.70% | -162.13% | 0.40x | 5.54x | GBX-2.83 Million |
| 2021 | -33.26% | -532.73% | 0.06x | 1.13x | GBX-8.02 Million |
| 2022 | -53.05% | -385.35% | 0.11x | 1.25x | GBX-11.01 Million |
| 2023 | -89.79% | -187.05% | 0.30x | 1.61x | GBX-9.51 Million |
| 2024 | -191.36% | -202.57% | 0.58x | 1.63x | GBX-10.77 Million |
Industry Comparison
This section compares Arecor Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,921,830
- Average return on equity (ROE) among peers: -110.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arecor Therapeutics PLC (AREC) | GBX2.86 Million | -166.97% | 0.84x | $3.33K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $997.94 |